Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
VSIQQ is indicated for:
Pharmacology
Brolucizumab is a human VEGF inhibitor. It binds to the three major isoforms of VEGF-A (VEGF 110, VEGF 121 and VEGF 165), and this stops VEGF-A from interacting with the receptors VEGFR-1 and VEGFR-2. With VEGF-A blocked, brolucizumab suppresses endothelial cell proliferation, neovascularization and vascular permeability.
Blood and fluid can leak from choroidal neovascularization (CNV), and this may cause retinal thickening or edema. On optical coherence tomography (OCT), increased retinal thickness and a build-up of intraretinal fluid (IRF) or subretinal fluid (SRF) are linked with nAMD and DME. Reductions in central retinal subfield thickness (CST) were seen across all treatment arms.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
For wet AMD, the recommended dose of BEOVU is 6 mg (0.05 mL of 120 mg/mL solution). You give it monthly (about every 25 to 31 days) for the first three doses. After that, one dose of 6 mg (0.05 mL) is given every 8 to 12 weeks.
Diabetic Macular Edema (DME)
For DME, BEOVU is also given as 6 mg (0.05 mL of 120 mg/mL solution). The first five doses are given every six weeks (about every 39 to 45 days). After these, one dose of 6 mg (0.05 mL of 120 mg/mL solution) is given every 8 to 12 weeks.
Pediatric Use
The safety and efficacy of BEOVU in pediatric patients has not been established.
Side Effects
People who receive Brolucizumab most often report blurred vision, cataract, bleeding on the white part of the eye (conjunctival hemorrhage), eye pain and vitreous floaters.
Cautions & Contraindications
Warnings & Precautions
Endophthalmitis and retinal detachment may occur after intravitreal injections, so patients should be told to report any symptoms that suggest either one without delay. With BEOVU (brolucizumab), retinal vasculitis and/or retinal vascular occlusion have also been reported, typically when there is intraocular inflammation. Patients should be told to report any change in vision without delay. Intraocular pressure (IOP) has been seen to rise within 30 minutes of an intravitreal injection. There is also a potential risk of arterial thromboembolic events (ATE) after intravitreal use of VEGF inhibitors.
Contraindications
Brolucizumab must not be given to patients who have an ocular or periocular infection. The same applies to anyone with active intraocular inflammation. It is also contraindicated in patients with known hypersensitivity to brolucizumab or to any of the excipients in Brolucizumab. Hypersensitivity reactions can show up as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.
Pregnancy & Breastfeeding
There are no adequate and well-controlled studies of BEOVU use in pregnant women. In an animal reproduction study, pregnant monkeys were given brolucizumab by injection into one eye once every 4 weeks, from organogenesis to birth. At 10-fold the maximum recommended human dose (MRHD) on a mg/kg basis, this caused fetal loss and a structural abnormality (bilateral absent metatarsal) in the offspring.
Nobody knows whether brolucizumab passes into human milk, what it does to a breastfed infant, or whether it affects milk production or excretion. Many drugs do transfer into human milk, and a breastfed child could absorb the drug and have adverse reactions. For that reason, breastfeeding is not recommended during treatment with Brolucizumab, or for at least one month after the last dose when treatment is stopped.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Keep Brolucizumab in a refrigerator at 2°C to 8°C, and don't let it freeze. Leave it in its outer carton so the light can't reach it. Before use, the unopened glass vial or sealed blister pack of Brolucizumab can stay at room temperature, 20°C to 25°C, for up to 24 hours.
Common questions about VSIQQ 6 mg/0.05 ml
What is VSIQQ 6 mg/0.05 ml IV Infusion?
VSIQQ 6 mg/0.05 ml IV Infusion is a medicine that contains Brolucizumab. It is made by Nevian Lifescience PLC.
What is VSIQQ used for?
VSIQQ is used for: Edema.
What are the side effects of VSIQQ?
People who receive Brolucizumab most often report blurred vision, cataract, bleeding on the white part of the eye (conjunctival hemorrhage), eye pain and vitreous floaters.
Can I take VSIQQ during pregnancy or while breastfeeding?
There are no adequate and well-controlled studies of BEOVU use in pregnant women. In an animal reproduction study, pregnant monkeys were given brolucizumab by injection into one eye once every 4 weeks, from organogenesis to birth. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store VSIQQ?
Keep Brolucizumab in a refrigerator at 2°C to 8°C, and don't let it freeze. Leave it in its outer carton so the light can't reach it.
Do I need a prescription for VSIQQ?
VSIQQ is a prescription (Rx) medicine. Take it as your doctor advises.